Keyword: Selexys Pharmaceuticals

HQ

3. Novartis

Novartis has in recent years remained a big hitter in the R&D stakes, and it continues its run with an impressive $9 billion spent on R&D last year—although that was only slightly up on the $8.93 billion it had spent the year before.